Second Quarterly Call Earnings Call Transcript
TapImmune has amended the criteria for patient enrollment in a Phase 2 clinical trial testing its T-cell vaccine, TPIV 200, in women with ovarian cancer.
A Florida-based biotechnology company has received fast-track designation from the Food and Drug Administration to develop immunotherapy treatments for ovarian and breast cancers.
Robin McCallum manages all aspects of CMC Operations for TapImmune’s cancer vaccine programs.
TapImmune says it is exploring licensing out its nucleic acid-based protein expression technology PolyStart to vaccine developers.
Ovarian Cancer News Today has covered TapImmune’s cancer vaccine for Ovarian and Breast Cancer, TPIV 200. Take a look.
The company is getting closer with several therapies under development, CEO Glynn Wilson said in a quarterly update last week.
Here is the complete transcript provided by Seeking Alpha from May 31st conference call and live webcast regarding 2017 first quarter clinical and corporate updates.
TapImmune Inc. has completed a multi-gram scale-up and GMP manufacturing of a second clinical lot of TPIV 200, which is a multi-epitope T-cell vaccine developed by the company that targets the folate receptor alpha
Targeting the immune system to fight cancer is not new: in 1891, New York bone sarcoma surgeon William B. Coley injected a patient with an inoperable malignant tumor with streptococcal organisms. His theory was that the resulting severe bacterial infection, erysipelas, would stimulate the immune system, shrinking the tumor.